10X Genomics v. Bruker Spatial Biology: Seven-Patent Spatial Transcriptomics Dispute Ends After 1,468 Days
10X Genomics and Prognosys Biosciences asserted seven US patents covering spatial transcriptomics technology against Bruker Spatial Biology’s GeoMx Digital Spatial Profiler platform in Delaware. After more than four years of litigation, the parties stipulated to dismiss all claims and counterclaims with prejudice, each side bearing its own costs.
Four-Year Spatial Transcriptomics War Ends in Mutual Walk-Away
Filed in May 2021 in the District of Delaware, this infringement action was brought by 10X Genomics, Inc. and Prognosys Biosciences, Inc. against Bruker Spatial Biology, Inc. and related Bruker entities. The plaintiffs asserted seven US patents directed at spatial transcriptomics — a technology that enables gene expression analysis with spatial resolution across tissue samples. The accused product was Bruker’s GeoMx Digital Spatial Profiler, a commercially significant platform for spatial biology research.
The case concluded on 13 May 2025 when the parties filed a stipulated dismissal under Federal Rule of Civil Procedure 41(a)(1)(A)(ii), dismissing all claims and counterclaims with prejudice. The with-prejudice designation is legally significant: neither 10X Genomics nor Prognosys may re-assert these specific claims against Bruker on the same patents arising from the same accused conduct, and Bruker’s counterclaims are likewise extinguished. Each party bears its own attorneys’ fees and costs, suggesting no party extracted a clearly superior litigation position at the point of settlement.
A 1,468-day duration for a seven-patent dispute is consistent with protracted inter partes challenges, claim construction proceedings, and potential expert discovery battles typical of high-stakes life sciences IP. The mutual cost-bearing arrangement and lack of any public damages figure suggests the resolution may reflect a broader commercial agreement or cross-licensing arrangement, though the public record is silent on any such terms. The involvement of former Solicitor General Paul D. Clement on Bruker’s side signals the seriousness with which the defendant approached its defence strategy.
Filing to Dismissed with Prejudice in 1468 days
1,468 days — over four years in Delaware District Court, well above the median for multi-patent biotech disputes
Dismissed with prejudice: what the stipulated exit means for both parties
Rule 41(a)(1)(A)(ii) stipulated dismissal with prejudice explained
A stipulated dismissal under FRCP 41(a)(1)(A)(ii) requires the agreement of all parties and, when entered with prejudice, operates as a final adjudication on the merits. Unlike a court-ordered dismissal, this mechanism gives both sides control over the exit terms. The with-prejudice designation bars any future re-filing of the same claims — it functions as a permanent resolution of the asserted infringement claims involving these seven patents against Bruker’s GeoMx platform.
Permanent, consent-based dismissal10X Genomics and Prognosys surrender their right to re-litigate
By agreeing to a with-prejudice dismissal, 10X Genomics and Prognosys permanently forfeited their ability to re-assert the seven patents in suit against Bruker’s GeoMx platform on the same grounds. The patents themselves remain in force and could be enforced against other parties. The mutual cost-bearing arrangement means no damages were publicly awarded, though a confidential commercial resolution — such as a licence or cross-licence — cannot be ruled out from the public record.
Patents intact; Bruker claims extinguishedBruker exits without a merits finding — counterclaims also gone
Bruker Spatial Biology and its affiliated entities secured dismissal of all plaintiff claims with prejudice, ending the immediate litigation threat to the GeoMx platform from these seven patents. However, Bruker’s own counterclaims — which may have included invalidity or non-infringement assertions — were also dismissed with prejudice. This prevents Bruker from re-litigating those counterclaims in a new action, though parallel IPR proceedings, if any were filed, would be governed by separate rules.
Litigation cleared; counterclaims also waivedSpatial transcriptomics IP remains a live enforcement risk across the sector
The seven patents asserted here cover foundational spatial transcriptomics methods and compositions. Their survival — unchallenged on the merits in this forum — means they remain available enforcement tools against other commercial players in spatial biology. Competitors offering spatial gene expression platforms should treat this outcome as a signal that 10X Genomics and Prognosys are willing to litigate extensively, even if this particular dispute resolved without a public merits ruling. FTO analysis against this portfolio remains commercially prudent.
Portfolio enforcement risk persistsFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | 10X Genomics, Inc. | Company | Spatial genomics platform company — holder of 7 spatial transcriptomics patents including US10472669Search in Eureka ↗ |
| Co-Plaintiff | Prognosys Biosciences, Inc. | Company | Search in Eureka ↗ |
| Defendant | Bruker Spatial Biology, Inc. | Company | Bruker Spatial Biology, Inc. — maker of the GeoMx Digital Spatial Profiler spatial biology instrumentSearch in Eureka ↗ |
| Plaintiff counsel | Alexandra M. Ewing | Attorney | Counsel for 10X Genomics, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Frederick L. Cottrell , III | Attorney | Counsel for 10X Genomics, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Gabriela Monasterio | Attorney | Counsel for 10X Genomics, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Jason James Rawnsley | Attorney | Counsel for 10X Genomics, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Joanna Schacter | Attorney | Counsel for 10X Genomics, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Kiley White | Attorney | Counsel for 10X Genomics, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Li Shen | Attorney | Counsel for 10X Genomics, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Matthew D. Powers | Attorney | Counsel for 10X Genomics, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Paul T. Ehrlich | Attorney | Counsel for 10X Genomics, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Robert L. Gerrity | Attorney | Counsel for 10X Genomics, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Ronald J. Pabis | Attorney | Counsel for 10X Genomics, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Samantha A. Jameson | Attorney | Counsel for 10X Genomics, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Stefani C. Smith | Attorney | Counsel for 10X Genomics, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Richards Layton & Finger PA | Law Firm | Representing 10X Genomics, Inc.Search in Eureka ↗ |
| Defendant counsel | Amanda Branch | Attorney | Counsel for Bruker Spatial Biology, Inc.Search in Eureka ↗ |
| Defendant counsel | Brian E. Farnan | Attorney | Counsel for Bruker Spatial Biology, Inc.Search in Eureka ↗ |
| Defendant counsel | C. Harker Rhodes | Attorney | Counsel for Bruker Spatial Biology, Inc.Search in Eureka ↗ |
| Defendant counsel | Christine E. Lehman | Attorney | Counsel for Bruker Spatial Biology, Inc.Search in Eureka ↗ |
| Defendant counsel | Christopher M. Pepe | Attorney | Counsel for Bruker Spatial Biology, Inc.Search in Eureka ↗ |
| Defendant counsel | Concord Cheung | Attorney | Counsel for Bruker Spatial Biology, Inc.Search in Eureka ↗ |
| Defendant counsel | Courtland L. Reichman | Attorney | Counsel for Bruker Spatial Biology, Inc.Search in Eureka ↗ |
| Defendant counsel | Derek C. Walter | Attorney | Counsel for Bruker Spatial Biology, Inc.Search in Eureka ↗ |
| Defendant counsel | Edward R. Reines | Attorney | Counsel for Bruker Spatial Biology, Inc.Search in Eureka ↗ |
| Defendant counsel | Kaitlin Paulson | Attorney | Counsel for Bruker Spatial Biology, Inc.Search in Eureka ↗ |
| Defendant counsel | Karnik F. Hajjar | Attorney | Counsel for Bruker Spatial Biology, Inc.Search in Eureka ↗ |
| Defendant counsel | Michael J. Farnan | Attorney | Counsel for Bruker Spatial Biology, Inc.Search in Eureka ↗ |
| Defendant counsel | Natalie C. Kennedy | Attorney | Counsel for Bruker Spatial Biology, Inc.Search in Eureka ↗ |
| Defendant counsel | Paul D. Clement | Attorney | Counsel for Bruker Spatial Biology, Inc.Search in Eureka ↗ |
| Defendant counsel | Sarah O. Jorgensen | Attorney | Counsel for Bruker Spatial Biology, Inc.Search in Eureka ↗ |
| Defendant counsel | Savannah H. Carnes | Attorney | Counsel for Bruker Spatial Biology, Inc.Search in Eureka ↗ |
| Defendant counsel | Yi Zhang | Attorney | Counsel for Bruker Spatial Biology, Inc.Search in Eureka ↗ |
| Defendant counsel | Yiqun Zhang | Attorney | Counsel for Bruker Spatial Biology, Inc.Search in Eureka ↗ |
| Defendant law firm | Farnan LLP | Law Firm | Representing Bruker Spatial Biology, Inc.Search in Eureka ↗ |
| Presiding judge | Judge Matthew F. Kennelly | Judge | Delaware District CourtSearch in Eureka ↗ |
Official order — verbatim text
The stipulated dismissal is framed as a mutual agreement under Rule 41(a)(1)(A)(ii), covering all claims and counterclaims with prejudice. The explicit with-prejudice designation is the operative legal term: it forecloses re-litigation of these specific claims in any future action between these parties. The symmetric cost-bearing provision — each party absorbing its own fees — suggests neither side extracted a decisive advantage through motion practice or discovery, and is consistent with a negotiated commercial resolution whose terms remain confidential.
US10472669 and Six Further Patents — Spatial Transcriptomics Methods & Compositions
The seven patents asserted in this action — US10472669, US10961566, US11001878, US10996219, US11008607, US10662467, and US10983113 — cover foundational aspects of spatial transcriptomics technology, including methods for capturing and analysing gene expression data while preserving the spatial coordinates of nucleic acids within tissue samples. The application dates underlying these patents span filings from approximately 2019 to 2021, reflecting a period of rapid innovation and patent prosecution in the spatial biology field. Prognosys Biosciences, a co-plaintiff, is a pioneer in spatially barcoded array technology and is widely regarded as a foundational licensor in this domain.
These patents sit at the core of a commercially contested technology space. Spatial transcriptomics — recognised by Science magazine as Method of the Year in 2020 — has become a critical tool in oncology, neuroscience, and drug development research. Control of foundational patent positions in this field carries significant commercial leverage, as downstream instrument and reagent revenues are substantial. The assertion of seven patents against a single accused product (the GeoMx platform) signals a broad claim of platform-level infringement, not merely peripheral feature overlap, and underscores the strategic importance of this IP portfolio to 10X Genomics’ competitive positioning.
Should you run an FTO against the 10X Genomics spatial transcriptomics portfolio?
Any organisation developing, commercialising, or acquiring spatial gene expression technology — including sequencing-based spatial platforms, imaging-based spatial proteomics tools, or hybridisation-based spatial RNA detection systems — should conduct a freedom-to-operate analysis against the seven patents litigated in this case. The with-prejudice dismissal of 10X Genomics’ claims against Bruker does not invalidate these patents or limit their enforceability against other parties. R&D teams building spatial capture arrays, barcoded probe systems, or tissue-section transcriptomic workflows are particularly exposed.
PatSnap Eureka’s FTO Search Agent can map your product’s technical features against the claim language of US10472669, US10961566, US11001878, US10996219, US11008607, US10662467, and US10983113 simultaneously, flagging overlap risk and identifying prior art that may support design-around or invalidity arguments. For in-house IP teams preparing for product launch or investor due diligence in the spatial biology sector, this analysis is a critical first step before any commercial deployment.
Run a freedom-to-operate analysis on US10472669B2 to assess your product’s exposure
Run FTO in Eureka →Similar Spatial Transcriptomics & Genomics Patent Disputes in Delaware
Cases involving foundational spatial transcriptomics and genomics patents in the District of Delaware, including related 10X Genomics enforcement actions and Bruker IP disputes.
What this case signals for the spatial biology IP landscape
A seven-patent, four-year dispute ending in mutual walk-away raises important questions for every player in the spatial transcriptomics market.
With-prejudice exit protects Bruker’s GeoMx but doesn’t validate it
No court found the seven asserted patents invalid or not infringed. The with-prejudice dismissal simply means the specific claims between these parties are over. Bruker’s GeoMx platform has not received a clean bill of health from any merits adjudication — a distinction that matters for investors, partners, and regulators assessing the platform’s IP risk profile.
Seven surviving spatial transcriptomics patents remain live threats to competitors
US10472669, US10961566, US11001878, US10996219, US11008607, US10662467, and US10983113 all remain in force. Any company developing or commercialising spatial gene expression technology — whether sequencing-based or imaging-based — should conduct a freedom-to-operate analysis against this portfolio before product launch or investor due diligence.
10X v Bruker — key questions answered
10X Genomics and Prognosys Biosciences asserted seven US patents: US10472669, US10961566, US11001878, US10996219, US11008607, US10662467, and US10983113. All cover aspects of spatial transcriptomics technology. The accused product was Bruker’s GeoMx Digital Spatial Profiler platform and associated instruments and reagents.
The stipulated dismissal with prejudice under FRCP 41(a)(1)(A)(ii) means all claims and counterclaims between the parties are permanently extinguished. Neither 10X Genomics nor Prognosys can re-assert the same patent claims against Bruker on the same grounds in any future action. Bruker’s counterclaims are similarly barred. The underlying patents remain valid and enforceable against third parties.
The 1,468-day duration is consistent with the complexity of a seven-patent life sciences dispute in Delaware, which typically involves extensive claim construction proceedings, inter partes review petitions at the USPTO, expert discovery, and potential summary judgment motions. The public record does not disclose the specific procedural milestones that extended the timeline, but the involvement of high-profile counsel on both sides — including former Solicitor General Paul Clement for Bruker — suggests aggressive litigation strategies on both sides.
The dismissal with prejudice protects Bruker’s GeoMx platform only from the specific claims brought by 10X Genomics and Prognosys in this action, on these seven patents. It does not represent a judicial finding of non-infringement or invalidity. Other patent holders in the spatial transcriptomics space could potentially assert different patents against the GeoMx platform. The platform has not received a merits-based clean bill of health from any court.
In US patent litigation, courts may award attorneys’ fees to the prevailing party in exceptional cases under 35 USC § 285. A mutual cost-bearing arrangement — where neither side receives fee recovery — suggests the case did not terminate with a clear prevailing party, and is consistent with a negotiated commercial resolution. It may also reflect that neither party pursued or succeeded on an exceptionality motion. The specific financial terms of any broader settlement remain confidential.
PatSnap Eureka searches patents and litigation data to answer instantly.